Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 5/20 | 0.34 |
| ▸ | PAK4 | O96013 | 2/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PAK6 | Q9NQU5 | 1/20 | 0.33 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11970439 | 0.85 | PAK4 (0.41) | MAP3K14PAK4PAK1PAK2PKN1 | |
| SCHEMBL12001598 | 0.78 | MAP3K14 (0.49) | CDC7CDK2MAP3K14ROCK1HRH4 | |
| SCHEMBL11970517 | 0.72 | ROCK1 (0.55) | CDC7CDK2MAP3K14ROCK1HRH4 | |
| SCHEMBL12001512 | 0.65 | MAP3K14 (0.40) | MAP3K14HRH4HRH3PAK4PIKFYVE | |
| SCHEMBL11970712 | 0.64 | MAP3K14 (0.53) | CDC7CDK2MAP3K14PAK4PAK1 | |
| SCHEMBL11970747 | 0.64 | PAK4 (0.55) | MAP3K14PAK4PIKFYVE | |
| SCHEMBL11970985 | 0.64 | MAP3K14 (0.46) | MAP3K14PAK4PIKFYVE | |
| SCHEMBL12001715 | 0.63 | CDC7 (0.36) | CDC7CDK2MAP3K14ROCK1PAK4 | |
| SCHEMBL12001469 | 0.63 | MAP3K14 (0.38) | CDC7CDK2MAP3K14ROCK1PARG | |
| SCHEMBL29605977 | 0.63 | CHRNA1 (0.35) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | CDC7 4283/4885CDK2 2025/4885MAP3K14 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.